Table II.
Classification of Individual Target Lesions
| Class name | CRYSTAL | APEC | Study 45 | OPUS | All studies | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALL | Cetuximab arm | KRASwt | ALL | ALL | KRASwt | ALL | Cetuximab arm | KRASwt | ALL | Cetuximab arm | KRASwt | |
| Liver | 884 (2867) | 434 (1420) | 227 (745) | 176 (525) | 51 (153) | 26 (89) | 265 (774) | 139 (421) | 63 (197) | 1376 (4319) | 800 (2519) | 487 (1546) |
| Lung | 252 (521) | 132 (262) | 63 (113) | 68 (155) | 10 (22) | 5 (7) | 49 (85) | 24 (43) | 8 (12) | 379 (783) | 234 (482) | 141 (284) |
| Lymph node | 261 (488) | 110 (193) | 62 (110) | 72 (141) | 4 (7) | 0 | 60 (113) | 33 (63) | 19 (37) | 397 (749) | 219 (404) | 148 (278) |
| Other | 250 (319) | 121 (151) | 73 (89) | 74 (102) | 12 (12) | 6 (6) | 70 (85) | 36 (42) | 21 (25) | 406 (518) | 243 (307) | 170 (218) |
| Total | 1647 (4195) | 797 (2026) | 425 (1057) | 390 (923) | 77 (194) | 37 (102) | 444 (1057) | 232 (569) | 111 (271) | 2540 (6369) | 1496 (3712) | 946 (2326) |
The number of class-related target lesions (cTLs, sum of lesions of a class for a patient) is presented in the table. Individual target lesions (iTLs, 1 or more than 1 per patient) are shown in parenthesis. ALL, target lesions from all patients included in the CICIL analysis. Cetuximab arm, patients who received cetuximab either as a monotherapy or in combination with chemotherapy: FOLFIRI (folinic acid + 5-fluorouracil + irinotecan) or FOLFOX (folinic acid + 5-fluorouracil + oxaliplatin). KRASwt, target lesions from KRASwt patients only. All patients in APEC and Study 45 studies received cetuximab; thus, the “Cetuximab arm” columns are omitted. APEC only included KRASwt patients: in this case only the “ALL” column is shown